-
China Cell Holding Subsidiary Submits Adalimumab Biosimilar Drug Listing Application
Time of Update: 2022-01-11
On December 16, China Cell Engineering, a holding subsidiary of China Cell Biology Group, submitted an application for the listing of Adalimumab (SCT630) biosimilar drug . SCT630 is a recombinant ful
-
Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression
Time of Update: 2022-01-11
1%; the lifetime prevalence of depression in Chinese adults is 6.
With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expand .
-
PD-1 new partner: BeiGene introduces LAG-3 antibody for US$772 million
Time of Update: 2022-01-11
In late March, BMS announced that the drug will be used in combination with the PD-1 monoclonal antibody Opdivo (nivolumab) to achieve the primary endpoint of PFS in the treatment of metastatic or unresectable melanoma initially treated patients with phase II/III clinical trials .
-
Hengrui subcutaneously injected PD-1 into the clinic
Time of Update: 2022-01-11
From a global perspective, Pfizer has also developed a subcutaneous PD-1 monoclonal antibody sasanlimab (PF-06801591), which has entered phase 3 clinical trials, combined with BCG in the treatment of high-risk non-muscle invasive bladder cancer .
-
TJ-CD4B bispecific antibody TJ-CD4B is approved for Phase 1 clinical trial in China
Time of Update: 2022-01-11
On December 15th, TJBio announced that CDE has officially approved the bispecific antibody TJ-CD4B (also known as ABL111) to treat solid tumors (including gastric cancer, esophageal-gastric junction adenocarcinoma, esophageal adenocarcinoma, and pancreatic duct adenocarcinoma).
-
Application progress of microneedle technology in transdermal drug delivery system
Time of Update: 2022-01-11
Microneedles are tiny needles with a diameter of 30~80μm and a length ranging from several hundred microns to several millimeters, which are made of silicon, metal or other materials through microelec
-
Pfizer's oral new crown drug has a final effective rate of 89% and is effective for the Omi Keron variant
Time of Update: 2022-01-11
On December 15th, Pfizer announced its new COVID-19 oral antiviral drug candidate Paxlovid (nirmatrelvir tablets (PF-07321332); ritonavir tablets) for the treatment of non-hospitalized patients with high risk of developing severe diseases in adults with COVID-19 infection The final analysis results of the randomized, double-blind phase II/III EPIC-HR study .
-
Zai Lab's Omacycline is approved and Hisun Pharmaceutical has the right to promote in China soon
Time of Update: 2022-01-11
ZL-2401 p-toluenesulfonate (Omadacycline, omacycline tosylate) is a new type of 9-aminomethylcycline drug, after chemical group modification based on the tetracycline antibiotic minocycline The resulting semi-synthetic compound has broad-spectrum antibacterial activity.
-
The world's first 15-valent HPV vaccine clinical trial application was accepted by the State Food and Drug Administration
Time of Update: 2022-01-11
Article source: Medical Rubik's Cube InfoOn December 15, the clinical trial application of the recombinant 15-valent human papillomavirus (HPV) vaccine (Escherichia coli) jointly developed by Beijing Kangleweishi and Liaoning Chengda Biotechnology Co.
Compared with the 9-valent HPV vaccine, it can prevent 90% of cervical cancer.
-
Tasly’s wholly-owned subsidiary, Memantine Hydrochloride Sustained-Release Capsules Obtained Drug Registration Certificate
Time of Update: 2022-01-11
On December 21, Tasly issued an announcement stating that its wholly-owned subsidiary, Diyi Pharmaceutical, had issued the Drug Registration Certificate for Memantine Hydrochloride Sustained Release Capsules approved and issued by the National Medical Products Administration for the treatment of moderate to severe Alzheimer’s.
-
The US claims that Biden signed sanctions against entities and individuals in 4 countries, including 4 Chinese pharmaceutical companies and 1 individual
Time of Update: 2022-01-11
S. Department of the Treasury website, the U.
S. 's so-called sanctions are based on combating drug abuse and addiction problems such as fentanyl, and it is accused of these companies and individuals "participating in the global illegal drug trade .
-
Tonghua Dongbao soluble sweetener lispro double insulin injection application clinically accepted
Time of Update: 2022-01-10
On December 27, Tonghua Dongbao issued an announcement stating that the company had recently obtained a notice on clinical trial application acceptance for soluble glorine-lispro insulin injection (THDB0207 injection) issued by CDE .
-
Looking forward to 2022, the pharmaceutical equipment industry will press the "shift button"!
Time of Update: 2022-01-10
In China’s pharmaceutical market, in recent years, with the continuous improvement of the living standards of our residents, the intensified population aging, and the promotion of a series of favorable pharmaceutical innovation and development policies, the continuous growth of R&D investment by local pharmaceutical companies has led to the rapid growth of domestic innovative drugs and emerging drugs.
-
Diabetes drugs have two more benefits, or to achieve both specimens
Time of Update: 2022-01-10
It is understood that in order to better benefit patients, many pharmaceutical companies in China are actively deploying innovative development of diabetes drugs .
According to reports, Suparutide (long-acting human-derived GLP-1), an innovative diabetes drug of Yinnuo Medicine, is currently undergoing clinical phase 3 research.
-
Maiwei Biologics Submits Marketing Applications for 2 Biosimilar Drugs of Disulumab
Time of Update: 2022-01-10
, And a comparative study of effectiveness and safety in patients with bone metastases from solid tumors.
Retrieved Dec 21, 2021, from https:// The marketing application of 9MW0311, a biosimilar drug of Desulumab injection by Maiwei Biologics, was accepted.
-
Merck's oral new crown drug Molnupiravir receives FDA emergency use authorization
Time of Update: 2022-01-10
On December 23, Merck/Ridgeback announced that the oral new crown drug Molnupiravir (MK-4482/EIDD-2801) has received emergency use authorization from the US FDA for the treatment of adult patients with mild to moderate COVID-19 .
-
A large number of enterprises will benefit from the publication of documents in various places to promote the development of the Chinese medicine industry
Time of Update: 2022-01-10
With the help of these policies, the industry expects that a large number of traditional Chinese medicine companies will usher in a larger market space and move toward a higher-quality development path through continuous inheritance of the essence, integrity and innovation .
-
Junshi Biologics was approved for subcutaneous injection of PD-1
Time of Update: 2022-01-10
Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
3 mg/kg, JS001sc administered by subcutaneous injection and Terry administered by intravenous injection The anti-tumor effect of prilimumab was equivalent, and no significant difference was seen .
-
Domestic innovative drug companies are ushering in an intensive harvest period!
Time of Update: 2022-01-10
In recent years, with the successive release of a series of favorable pharmaceutical innovation policies such as speeding up the review and approval of new drugs, as well as the high R&D investment of local innovative drug companies, the continuous breakthroughs in key technologies have made domestic innovative drug companies usher in an intensive harvest period.
-
Sansheng Guojian SSGJ-706 injection obtained the "Notice of Drug Clinical Trial Approval"
Time of Update: 2022-01-10
Studies have shown that dual antibody inhibitors that target two different targets at the same time have a good therapeutic effect and are compared with two single The incidence of adverse reactions of anti-combination drugs may be low .
